Dupilumab improves health‐related quality of life in patients with chronic rhinosinusitis with nasal polyposis
| Autor: | Vijay N. Joish, Neil M.H. Graham, Adeline Abbe, Gianluca Pirozzi, Claus Bachert, P. Gevaert, Robert M. Naclerio, Heribert Staudinger, Jingdong Chao, Puneet Mahajan, Nikhil Amin, Joaquim Mullol, Chunpeng Fan, Christine Taniou, Peter Hellings, Daniel L. Hamilos, Asif Khan, Leda Mannent |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male medicine.medical_specialty Visual analogue scale medicine.medical_treatment Immunology Anti-Inflammatory Agents Mometasone furoate Antibodies Monoclonal Humanized Placebo law.invention Nasal Polyps Double-Blind Method Randomized controlled trial law Internal medicine Clinical endpoint Humans Immunology and Allergy Medicine Patient Reported Outcome Measures Sinusitis Rhinitis business.industry Middle Aged medicine.disease Dupilumab Treatment Outcome Nasal spray Chronic Disease Quality of Life Female business Mometasone Furoate medicine.drug |
| Zdroj: | Allergy. 75:148-157 |
| ISSN: | 1398-9995 0105-4538 |
| DOI: | 10.1111/all.13984 |
| Popis: | Background Chronic rhinosinusitis with nasal polyposis (CRSwNP) negatively affects health-related quality of life (HRQoL). In a previously reported randomized clinical trial (NCT01920893), addition of dupilumab to mometasone furoate in patients with CRSwNP refractory to intranasal corticosteroids (INCS) significantly improved endoscopic, radiographic, and clinical endpoints and patient-reported outcomes. The objective of this analysis was to examine the impact of dupilumab treatment on HRQoL and productivity using secondary outcome data from this trial. Methods Following a 4-week mometasone furoate nasal spray run-in, patients were randomized to commence subcutaneous dupilumab (600 mg loading dose, then 300 mg once weekly for 15 weeks [n = 30], or matched placebo [n = 30]). Outcomes included scores on the CRS disease severity visual analog scale (VAS), 22-item Sino-Nasal Outcome Test (SNOT-22), 5-dimension EuroQoL (EQ-5D) general health status VAS, and 36-item Short-Form Health Survey (SF-36) for HRQoL and nasal polyp-related healthcare resource use questionnaires. Results Following 16 weeks of treatment, the proportion of patients with moderate-to-severe CRSwNP (VAS > 3-10) decreased from 86.2% to 21.4% with dupilumab and 88.0% to 84.2% with placebo. Dupilumab (vs placebo) resulted in significantly greater improvement in HRQoL, based on SNOT-22, SF-36, and EQ-5D VAS scores. The dupilumab group had a significantly lower adjusted annualized mean number of sick leave days (0.09, vs 4.18 with placebo, P = .015) and significantly greater improvement (vs placebo) in the SNOT-22 item "reduced productivity." Conclusions In adults with CRSwNP refractory to treatment with INCS alone, the addition of dupilumab reduced disease severity, significantly improved HRQoL, and improved productivity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text